Results 31 to 40 of about 212,694 (168)

Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai, Natalie Szpakowski, Albree Tower‐Rader, Barb Bittel, Agostina Fava, Susan Ospina, Bo Xu, Maran Thamilarasan, Amgad Mentias, Nicholas G. Smedira, Zoran B. Popovic   +10 more
doaj   +1 more source

Two Hearts at Risk

JACC: Case Reports, 2020
Hypertrophic obstructive cardiomyopathy (HOCM) increases the risk for mother and fetus during pregnancy. Alcohol septal ablation (ASA) is an established procedure in nonpregnant patients with HOCM. In this report, we present a case of a 29-year-old woman
Weng-Tein Gi, MD, MSc, Ali Amr, MD, Farbod Sedaghat-Hamedani, MD, Elham Kayvanpour, MD, Isabell Mohr, BSc, Manuela Meder, MD, Omid Shirvani Samani, MD, Herbert Fluhr, MD, Hugo A. Katus, MD, Benjamin Meder, MD   +9 more
doaj   +1 more source

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown.
Milla E. Arabadjian, Maria C. Reuter, Alexandra Stepanovic, Mark V. Sherrid, Daniele Massera   +4 more
doaj   +1 more source

Self- and Goal-Directed Valsalva Maneuver vs Exercise in Eliciting Left Ventricular Outflow Tract Obstruction

JACC: Advances
Background: In symptomatic patients with hypertrophic cardiomyopathy (HCM), eliciting left ventricular outflow tract obstruction (LVOTO) is critical. A self-directed Valsalva (SDV) and exercise (EX) are frequent tools used to unmask obstruction in HCM ...
Aakash Bavishi, MD, MSCI, John Fritzlen, MD, Kutaiba Nazif, DO, Marybeth Soutar, MS, Margaret Kurnides, RDCS, Heather Speer, RDCS, Glenda Oyarce, RCS, Karen Richards, RN, Cara Flahive, RN, Matthew W. Martinez, MD   +9 more
doaj   +1 more source

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2019
Background: Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage revealed upregulation of endothelin (ET1) signaling in both mutants, but TGFβ ...
Yamin Liu, Yamin Liu, Junaid Afzal, Junaid Afzal, Styliani Vakrou, Gabriela V. Greenland, Gabriela V. Greenland, C. Conover Talbot, Virginia B. Hebl, Yufan Guan, Rehan Karmali, Jil C. Tardiff, Leslie A. Leinwand, Jeffrey E. Olgin, Samarjit Das, Ryuya Fukunaga, M. Roselle Abraham, M. Roselle Abraham   +17 more
doaj   +1 more source

Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Milind Y. Desai, Andrew Gaballa, Yuichiro Okushi, Mohammed Abusafia, Shada Jadam, Katy Rutkowski, Susan Ospina, Sanaa Sultana, Maran Thamilarasan, Craig Asher, Zoran B. Popovic, Bo Xu   +11 more
doaj   +1 more source

Weight loss in hypertrophic cardiomyopathy: A clinical case series

International Journal of Cardiology. Cardiovascular Risk and Prevention, 2023
Background: Obesity is prevalent among patients with hypertrophic cardiomyopathy (HCM). Obese HCM patients have greater wall thickness, LV mass, worse hemodynamic function and NYHA class. Weight loss may favorably influence the HCM phenotype.
Maria C. Reuter, Daniele Massera, Leon Axel, Larry A. Latson, Jonathan M. Goldstein, Alexandra Stepanovic, Mark V. Sherrid   +6 more
doaj   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid, Daniel G. Swistel, Iacopo Olivotto, Maurizio Pieroni, Omar Wever‐Pinzon, Katherine Riedy, Richard G. Bach, Mustafa Husaini, Sharon Cresci, Alex Reyentovich, Daniele Massera, Martin S. Maron, Barry J. Maron, Bette Kim   +13 more
doaj   +1 more source

Cardiomyopathies [PDF]

Circulation Research, 2017
The nonischemic cardiomyopathies are a diverse group of cardiac disorders that frequently cause heart failure and death and are now recognized with increasing frequency. There has been substantial progress in the clinical recognition and understanding of the natural history of these conditions. Well-established and new techniques of cardiac imaging are
openaire   +2 more sources

Cardiac Myxoma in a Patient With Hypertrophic Cardiomyopathy

JACC: Case Reports, 2020
We report a rare case of concomitant hypertrophic cardiomyopathy and cardiac myxoma without LEOPARD syndrome. Additionally, 6 similar cases were systemically reviewed, and the characteristics of this first-ever studied patient group were summarized ...
Weng-Tein Gi, MD, MSc, Farbod Sedaghat-Hamedani, MD, Omid Shirvani Samani, MD, Elham Kayvanpour, MD, Esther Herpel, MD, Rawa Arif, MD, Johannes Riffel, MD, Derliz Mereles, MD, Hugo A. Katus, MD, Benjamin Meder, MD   +9 more
doaj   +1 more source